⁶⁸Ga-DOTATATE PET/CT Findings in Suspected Tumor-Induced Osteomalacia

A Prospective Descriptive Study

Authors

DOI:

https://doi.org/10.59667/sjoranm.v24i1.18

Keywords:

tumor-induced osteomalacia, phosphaturic mesenchymal tumors, 68Ga-DOTATATE, positron emission tomography, computed tomography

Abstract

Objective. To describe ⁶⁸Ga-DOTATATE PET/CT findings and their relationship to available histopathology in patients referred for suspected tumor-induced osteomalacia. Methods. This prospective descriptive study included 18 patients evaluated at a referral center in Argentina. Results. The median age was 47.5 years and 13 of 18 patients were women. The reported median SUVmax was 17.2 (interquartile range 6.27–30.6). Lesions were most frequently reported in the appendicular skeleton. Eight patients had histologically confirmed phosphaturic mesenchymal tumors (PMTs). Two of these eight patients had lesions with ill-defined margins and involvement of soft tissue and facial bones. Median SUVmax was numerically higher in the PMT group. The difference was not statistically significant as reported. Conclusion. In this referral cohort, ⁶⁸Ga-DOTATATE PET/CT helped localize and characterize lesions in patients with suspected tumor-induced osteomalacia. Confirmed PMTs showed variable morphology. The findings support descriptive interpretation in conjunction with histopathology and clinical assessment.

Author Biographies

  • Prof. Dr. María Bastianello, MD PhD, Molecular Imaging and Metabolic Therapy, Hospital Universitario CEMIC, Buenos Aires, Argentina

    Professor and Head of Division of Molecular Imaging and Metabolic Therapy, Hospital Universitario CEMIC, Buenos Aires, Argentina

    Argentina Tumor-Induced Osteomalacia Study Group, Buenos Aires, Argentina

  • Roxana Chirico, Molecular Imaging and Metabolic Therapy, Hospital Universitario CEMIC, Buenos Aires, Argentina

    Medica Especialista en Medicina Nuclear. Coordinadora de la Carrera Especialista en Imagenes Moleculares y Terapia . CEMIC. IUC.UNSAM Docente IUC y UNSAM, Buenos Aires, Argentina

    Molecular Imaging and Metabolic Therapy, Hospital Universitario CEMIC, Buenos Aires, Argentina

    Argentina Tumor-Induced Osteomalacia Study Group, Buenos Aires, Argentina

  • Matías Cimín, Molecular Imaging and Metabolic Therapy, Hospital Universitario CEMIC, Buenos Aires, Argentina

    Medico Especialista en Medicina Nuclear y Medico de planta de la Seccion de imagenes moleculares y terapia metabolica en CEMIC, Buenos Aires, Argentina

    Molecular Imaging and Metabolic Therapy, Hospital Universitario CEMIC, Buenos Aires, Argentina

    Argentina Tumor-Induced Osteomalacia Study Group, Buenos Aires, Argentina

  • María Belén Zanchetta, Institute of Metabolic Diagnosis and Research (IDIM), Buenos Aires, Argentina

    Professor of Bone Disordes at the University of Salvador and is the Medical Director of the Institute of Metabolic Diagnosis and Research (IDIM)

References

1. Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A, et al. Tumor-induced Osteomalacia: A Comprehensive Review. Endocr Rev. 2023;44(2):323-53, doi: https://doi.org/10.1210/endrev/bnac026 DOI: https://doi.org/10.1210/endrev/bnac026

2. Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT Tumor-Induced Osteomalacia. Calcif Tissue Int. 2021;108(1):128-42, https://doi.org/10.1007/s00223-020-00691-6 DOI: https://doi.org/10.1007/s00223-020-00691-6

3. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30, https://doi.org/10.1097/00000478-200401000-00001 DOI: https://doi.org/10.1097/00000478-200401000-00001

4. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500-5, https://doi.org/10.1073/pnas.101545198 DOI: https://doi.org/10.1073/pnas.101545198

5. Chong J, Leung B, Poole P Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(11):CD002309, https://doi.org/10.1002/14651858.CD002309.pub4 DOI: https://doi.org/10.1002/14651858.CD002309.pub4

6. Clifton-Bligh RJ, Hofman MS, Duncan E, Sim I-W, Darnell D, Clarkson A, et al. Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab. 2013;98(2):687-94, https://doi.org/10.1210/jc.2012-3642 DOI: https://doi.org/10.1210/jc.2012-3642

7. Kobayashi H, Makise N, Ushiku T, Ito N, Koga M, Shinoda Y, et al. Infiltrative nature of tumor-induced osteomalacia lesions in bone: Correlation between radiological and histopathological features. Journal of Orthopaedic Science. 2019;24(5):900-5, https://doi.org/10.1016/j.jos.2019.02.005 DOI: https://doi.org/10.1016/j.jos.2019.02.005

8. Zuo Q, Wang H, Li W, Niu X, Huang Y, Chen J, et al. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients. BMC Musculoskelet Disord. 2017;18(1), https://doi.org/10.1186/s12891-017-1756-1 DOI: https://doi.org/10.1186/s12891-017-1756-1

9. Jerkovich F, Nuñez S, Mocarbel Y, Pignatta A, Elías N, Cassinelli H, et al. Burden of Disease in Patients With Tumor‐Induced Osteomalacia. JBMR Plus. 2021;5(2):e10436, https://doi.org/10.1002/jbm4.10436 DOI: https://doi.org/10.1002/jbm4.10436

10. Zanchetta MB, Jerkovich F, Nuñez S, Mocarbel Y, Pignatta A, Elías N, et al. Impaired bone microarchitecture and strength in patients with tumor-induced osteomalacia. Journal of Bone and Mineral Research. 2020;36(8):1502-9, https://doi.org/10.1002/jbmr.4325 DOI: https://doi.org/10.1002/jbmr.4325

11. Hesse E, Rosenthal H, Bastian L Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med. 2007;357(4):422-4, https://doi.org/10.1056/NEJMc070347 DOI: https://doi.org/10.1056/NEJMc070347

12. Gonzalez MR, Patel N, Connolly JJ, Hung YP, Chang CY, Lozano-Calderon SA Phosphaturic mesenchymal tumor: management and outcomes of ten patients treated at a single institution. Skeletal Radiol. 2024;53(8):1495-506, https://doi.org/10.1007/s00256-024-04614-6 DOI: https://doi.org/10.1007/s00256-024-04614-6

13. Dahir K, Zanchetta MB, Stanciu I, Robinson C, Lee JY, Dhaliwal R, et al. Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience. Journal of the Endocrine Society. 2021;5(9):bvab099, https://doi.org/10.1210/jendso/bvab099 DOI: https://doi.org/10.1210/jendso/bvab099

14. Liu Y, He H, Zhang C, Zeng H, Tong X, Liu Q Phosphaturic Mesenchymal Tumors: Rethinking the Clinical Diagnosis and Surgical Treatment. JCM. 2022;12(1):252, https://doi.org/10.3390/jcm12010252 DOI: https://doi.org/10.3390/jcm12010252

15. Abrahamsen B, Smith CD, Minisola S Epidemiology of Tumor-Induced Osteomalacia in Denmark. Calcif Tissue Int. 2021;109(2):147-56, https://doi.org/10.1007/s00223-021-00843-2 DOI: https://doi.org/10.1007/s00223-021-00843-2

16. Nandam N, Ejaz S, Ahrens W, Styner M A Normal FGF23 Does Not Preclude Tumor‐Induced Osteomalacia. JBMR Plus. 2021;5(2), https://doi.org/10.1002/jbm4.10438 DOI: https://doi.org/10.1002/jbm4.10438

SJORANM article cover, Vol. 24 No. 1 (2025). Holographic symbolic illustration for article 87.

Downloads

Published

2025-10-31

Data Availability Statement

The datasets generated during the current study are available from the corresponding author on reasonable request.

Issue

Vol. 24 No. 1 (2025)

Section

Research Articles

License

Copyright (c) 2025 Prof. Dr. María Bastianello, MD PhD, Roxana Chirico, Matías Cimín, María Belén Zanchetta

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This license requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, even for commercial purposes.

How to Cite

Bastianello, M., Chirico, R., Cimín, M., & Zanchetta, M. B. (2025). ⁶⁸Ga-DOTATATE PET/CT Findings in Suspected Tumor-Induced Osteomalacia: A Prospective Descriptive Study. Swiss Journal of Radiology and Nuclear Medicine, 24(1), 15-21. https://doi.org/10.59667/sjoranm.v24i1.18

Share

Similar Articles

1-10 of 26

You may also start an advanced similarity search for this article.